The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs
Open accessAbstract
Nanocrystals, a carrier-free colloidal delivery system in nano-sized range, is an interesting approach for poorly soluble drugs. Nanocrystals provide special features including enhancement of saturation solubility, dissolution velocity and adhesiveness to surface/cell membranes. Several strategies are applied for nanocrystals production including precipitation, milling, high pressure homogenization and combination methods such as NanoEdge™, SmartCrystal and Precipitation-lyophilization-homogenization (PLH) technology. For oral administration, many publications reported useful advantages of nanocrystals to improve in vivo performances i.e. pharmacokinetics, pharmacodynamics, safety and targeted delivery which were discussed in this review. Additionally, transformation of nanocrystals to final formulations and future trends of nanocrystals were also described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
KECK, C., & MULLER, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.009 · Cited by 1,061
Nanosizing — Oral formulation development and biopharmaceutical evaluation
Kesisoglou, F., Panmai, S., & Wu, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.003 · Cited by 1,055
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Liversidge, G. G., & Cundy, K. C. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)00122-y · Cited by 739
Van Eerdenbrugh, B., Van den Mooter, G., & Augustijns, P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.023 · Cited by 717
Müller, R. H., Gohla, S., & Keck, C. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.007 · Cited by 702
Nanonization strategies for poorly water-soluble drugs
Chen, H., Khemtong, C., Yang, X., Chang, X., & Gao, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.009 · Cited by 642
Merisko-Liversidge, E., & Liversidge, G. G. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.007 · Cited by 608
Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
Merisko-Liversidge, E. M., & Liversidge, G. G. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310946 · Cited by 579
Sinha, B., Müller, R. H., & Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.019 · Cited by 523
Jinno, J.-I., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.013 · Cited by 510
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
Jacobs, C., & Müller, R. H. (2002) · Pharmaceutical Research · doi:10.1023/a:1014276917363 · Cited by 439
Drug nanocrystals in the commercial pharmaceutical development process
Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.034 · Cited by 432
Gao, L., Zhang, D., & Chen, M. (2008) · Journal of Nanoparticle Research · doi:10.1007/s11051-008-9357-4 · Cited by 420
Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen
Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., & Puglisi, G. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00057-x · Cited by 350
Production and characterization of Hesperetin nanosuspensions for dermal delivery
Mishra, P. R., Shaal, L. A., Müller, R. H., & Keck, C. M. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.12.030 · Cited by 308
Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals
Müller, R. H., Runge, S., Ravelli, V., Mehnert, W., Thünemann, A. F., & Souto, E. B. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.045 · Cited by 304
Liversidge, G. G., & Conzentino, P. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)00148-c · Cited by 294
Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs
KASSEM, M., ABDELRAHMAN, A., GHORAB, M., AHMED, M., & KHALIL, R. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.011 · Cited by 279
Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., et al. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.08.001 · Cited by 275
Ali, H. S. M., York, P., Ali, A. M. A., & Blagden, N. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.007 · Cited by 253
Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide
Jacobs, C., Kayser, O., & Müller, R. H. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00412-3 · Cited by 232
Peters, K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.1.77 · Cited by 228
Formulation of amphotericin B as nanosuspension for oral administration
Kayser, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00686-5 · Cited by 186
Nanoparticulate Drug Delivery Systems
(2007) · CRC Press eBooks · doi:10.1201/9781420008449 · Cited by 171
Lutein nanocrystals as antioxidant formulation for oral and dermal delivery
Mitri, K., Shegokar, R., Gohla, S., Anselmi, C., & Müller, R. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.026 · Cited by 163
Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal
Zhang, J., Lv, H., Jiang, K., & Gao, Y. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.023 · Cited by 159
The relationship between particle size and solubility
Buckton, G., & Beezer, A. E. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90184-4 · Cited by 143
Shaal, L. A., Shegokar, R., & Müller, R. H. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.018 · Cited by 142
Mou, D., Chen, H., Wan, J., Xu, H., & Yang, X. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.034 · Cited by 134
Ganta, S., Paxton, J. W., Baguley, B. C., & Garg, S. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.022 · Cited by 122
Bottom-Up Preparation Techniques for Nanocrystals of Lipophilic Drugs
de Waard, H., Frijlink, H. W., & Hinrichs, W. L. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0323-3 · Cited by 109
New Method for the Effective Production of Ultrafine Drug Nanocrystals
Möschwitzer, J. P., & Müller, R. H. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.480 · Cited by 100
Langguth, P., Hanafy, A., Frenzel, D., Grenier, P., Nhamias, A., Ohlig, T., Vergnault, G., & Spahn-Langguth, H. (2005) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-52182 · Cited by 98
Niwa, T., Miura, S., & Danjo, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.013 · Cited by 90
Kesisoglou, F., & Mitra, A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9383-0 · Cited by 81
Zhai, X., Lademann, J. M., Keck, C. M., & Müller, R. H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.04.060 · Cited by 80
Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension
Li, W., Yang, Y., Tian, Y., Xu, X., Chen, Y., Mu, L., Zhang, Y., & Fang, L. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.059 · Cited by 77
Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation
Sauron, R. É., Wilkins, M. R., Jessent, V., Dubois, A., Maillot, C., & Weil, A. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44064 · Cited by 72
Kayser, O. (2001) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00640-2 · Cited by 71
Nanoparticulate Drug-Delivery Systems
Thassu, D., Pathak, Y. V., & Deleers, M. (2007) · Drugs and the pharmaceutical sciences · doi:10.1201/9781420008449.ch1 · Cited by 55
Morakul, B., Suksiriworapong, J., Leanpolchareanchai, J., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.09.022 · Cited by 46
Self-citationNanocrystals of Poorly Soluble Drugs for Oral Administration
Bushrab, F. N., & Müller, R. H. (2003) · Cited by 43
In vivo evaluation of matrix pellets containing nanocrystalline ketoprofen
Vergote, G. J., Vervaet, C., Driessche, I. V., Hoste, S., Smedt, S. C. D., Demeester, J., Jain, R. A., Ruddy, S., & Remon, J. P. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00114-x · Cited by 42
Handbook of Materials for Nanomedicine
Torchilin, V. P. (2010) · Pan Stanford eBooks · doi:10.1201/b11121 · Cited by 31
Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis
Sultana, S., Talegaonkar, S., Ali, R., Mittal, G., Ahmad, F. J., & Bhatnagar, A. (2012) · Journal of Microencapsulation · doi:10.3109/02652048.2012.655428 · Cited by 27
smartCrystals — Review of the Second Generation of Drug Nanocrystals
Keck, C. M., & Müller, R. H. (2011) · doi:10.1201/9780429111570-13 · Cited by 19
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. (2022) · Biomedicines · doi:10.3390/biomedicines10092055 · Cited by 704
Nanoparticles: Taking a Unique Position in Medicine
Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, Ł., Hasanin, M., Kattali, M., Haponiuk, J., & Thomas, S. (2023) · Nanomaterials · doi:10.3390/nano13030574 · Cited by 480
Multifunctional nanocrystals for cancer therapy: a potential nanocarrier
Joseph, E., & Singhvi, G. (2019) · Nanomaterials for Drug Delivery and Therapy · doi:10.1016/b978-0-12-816505-8.00007-2 · Cited by 367
Metadata
- Authors
- Junyaprasert, V. B., & Morakul, B.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 10
- Issue
- 1
- Pages
- 13-23
- ISSN
- 1818-0876 (ISSN-L)
- OpenAlex
- W2105502591
- Cited by
- 443
- References
- 47
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.